Laidlaw Starts BiomX (PHGE) at Buy

Laidlaw initiates coverage on BiomX (NYSE: PHGE) with a Buy rating and a price target of $2.50.

The analyst commented, "PHGE is a mid-clinical stage biotech company focusing on developing phage-based anti-infective therapies. PHGE currently has two Phase II studies in CF and DFO, respectively, underway with topline readout expected in 3Q25 and 1Q25 ...With the novel and clinical promising phage-based therapeutics pipeline in place, we view PHGE shares are undervalued at current levels. We are recommending PHGE shares to long-term oriented investors with higher risk tolerance. Our 12-month $2.50 price target is based on forward P/E, and NPV-driven sum-of-the-parts analyses."

For an analyst ratings summary and ratings history on BiomX click here. For more ratings news on BiomX click here.

Shares of BiomX closed at $0.34 yesterday.

You May Also Be Interested In

• Northland Starts Nephros (NEPH) at Market Perform
• Cantor Fitzgerald Reiterates Overweight Rating on DBV Technologies S.A (DBVT)
• William Blair Upgrades BJ's Restaurants (BJRI) to Outperform